Adjuvant Capital
Adjuvant Capital is a life sciences investment fund that backs ambitious companies developing drugs, vaccines, diagnostics, medical devices, and other technologies to address critical global public health challenges. It focuses on historically overlooked market segments, leveraging expertise to translate opportunities into social and financial returns. The firm's investment model is heavily influenced by global trends such as climate change and antimicrobial resistance.
Offices: New York (United States), Zurich (Switzerland), New York, NY 11217, US, San Francisco, CA 94133, US
Investment Stages: Series A, Series B, Series C
Markets: Life sciences, Drugs, Vaccines, Diagnostics, Medical devices
Founded Year: 2012
Investor Type: Venture Capital
Portfolio Companies: LimmaTech Biologics, Memo Therapeutics, Curevo Vaccine, Antiva Biosciences, Pulmocide, Excision BioTherapeutics, Frontier Nutrition, VitriVax, MinervaX, Evofem, Univercells, YS Biopharma, ChromaCode, 54gene, Codagenix, AN2 Therapeutics, Themis, InDevR, X-Vax
Website: https://adjuvantcapital.com
Team Page: https://adjuvantcapital.com/team/
Portfolio Link: https://adjuvantcapital.com/portfolio/
LinkedIn: https://www.linkedin.com/company/adjuvant-capital
Twitter: https://twitter.com/adjcap
Crunchbase: https://www.crunchbase.com/organization/adjuvant-capital
Comments
No comments yet. Be the first to comment!